Balance Sheet Components

3 Months Ended

Mar. 31, 2025

Balance Sheet Related Disclosures [Abstract]

Goodwill

Goodwill was $754.3 million and $745.8 million as of March 31, 2025 and December 31, 2024, respectively. The changes in the carrying amounts of goodwill during the three months ended March 31, 2025 were due to foreign currency translation. The Company has not recorded any impairment related to goodwill.

Intangible Assets, Net

Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):


	March 31, 2025						December 31, 2024						Weighted Average Remaining Amortization Period (Years)
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Percepta product technology	$	16,000	$	(10,667)	$	5,333	$	16,000	$	(10,400)	$	5,600	5
Prosigna product technology	4,120		(1,465)		2,655		4,120		(1,396)		2,724		10
Decipher product technology	90,000		(36,484)		53,516		90,000		(34,234)		55,766		6
Decipher trade names	4,000		(3,243)		757		4,000		(3,043)		957		1
C2i developed technology	25,300		(1,967)		23,333		25,300		(1,546)		23,754		14
Total finite-lived intangibles	139,420		(53,826)		85,594		139,420		(50,619)		88,801		8.3
In-process research and development	13,500		—		13,500		13,500		—		13,500
Total intangible assets	$	152,920	$	(53,826)	$	99,094	$	152,920	$	(50,619)	$	102,301

Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized.

Amortization expense of $3.2 million and $3.7 million was recognized for the three months ended March 31, 2025 and 2024, respectively.

The estimated future aggregate amortization expense as of March 31, 2025 is as follows (in thousands of dollars):


Year Ending December 31,	Amounts
2025 remainder of year	$	9,621
2026	12,185
2027	12,028
2028	12,028
2029	12,028
Thereafter	27,704
Total	$	85,594

Supplies and Inventory

Supplies consisted of lab supplies and reagents to be used in the performance of testing services. Inventory related to finished and semi-finished goods used in the assembly of diagnostic kits related to product sales as well as raw materials consumed in the contract manufacturing process. As of March 31, 2025 and December 31, 2024, supplies and inventory consisted of the following (in thousands of dollars):


	March 31, 2025		December 31, 2024
Supplies	$	18,360	$	17,876
Inventory	5,894		3,874
Total supplies and inventory	$	24,254	$	21,750

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands of dollars):


	March 31, 2025		December 31, 2024
Accrued compensation expenses	$	18,699	$	30,595
Accrued other	17,229		13,231
Total accrued liabilities	$	35,928	$	43,826